Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Provide patients with serious AdV infection or disease access to treatment with BCV.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Brincidofovir
Eligibility
Inclusion Criteria:
- Confirmed serious AdV infection based on clinical symptoms and laboratory testing
showing AdV in the blood or other bodily fluids
- Able to swallow medication, either tablet or liquid
Exclusion Criteria:
- Previous dosing with Brincidofovir
- If female, not pregnant or trying to become pregnant
Ages Eligible for Study
2 Months - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.